Cell No. : Cell Name
RCB4476 : Ba/F3
update : 2024/09/20
|
Comment | Mouse pro-B cell line derived from C3H strain. IL-3 dependent. Information |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Tani, Kenzaburo
|
Year of deposit |
2012
|
Animal |
_mouse
< Mammals
|
Strain name |
C3H
|
Tissue |
bone marrow
|
Classification |
other
|
|
Lifespan |
infinite
|
Morphology |
lymphocyte-like
|
Cellosaurus(Expasy) |
CVCL_0161
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
Culture medium |
|
RPMI1640 + 10% FBS + 10ng/ml mouse IL-3
|
Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 10 split
|
SC frequency |
|
Subculture : 3 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
Animal PCR |
|
OK
|
SSLP(mouse) |
|
OK
|
Images |
deposit info | lot info |
|
|
Reference information |
Reference |
3
|
User's Publication |
6
|
User's Publication |
21874
Ochi N, Miyake N, Takeyama M, Yamane H, Fukazawa T, Nagasaki Y, Kawahara T, Ichiyama N, Kosaka Y, Mimura A, Nakanishi H, Hiraki A, Kiura K, Takigawa N.
The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells.
Biochim Biophys Acta Gen Subj
2024
1868(10):130675
PubMed ID: 39059510
DOI: 10.1016/j.bbagen.2024.130675
|
21413
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R.
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Nat Cancer
2023
4(9):1345-1361
PubMed ID: 37743366
DOI: 10.1038/s43018-023-00630-y
|
20690
Miettinen TP, Ly KS, Lam A, Manalis SR.
Single-cell monitoring of dry mass and dry mass density reveals exocytosis of cellular dry contents in mitosis.
Elife
2022
11
PubMed ID: 35535854
DOI: 10.7554/eLife.76664
|
15835
Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y.
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
Cancer Sci
2021
112(5):1963-1974
PubMed ID: 33544933
DOI: 10.1111/cas.14839
|
13269
Kang JH, Katsikis G, Li Z, Sapp KM, Stockslager MA, Lim D, Vander Heiden MG, Yaffe MB, Manalis SR, Miettinen TP.
Monitoring and modeling of lymphocytic leukemia cell bioenergetics reveals decreased ATP synthesis during cell division.
Nat Commun
2020
PubMed ID: 33020492
DOI: 10.1038/s41467-020-18769-y
|
17098
Miettinen TP, Kang JH, Yang LF, Manalis SR.
Mammalian cell growth dynamics in mitosis
Elife
2019
8:e44700.
PubMed ID: 31063131
DOI: 10.7554/eLife.44700
|